TIP_link_300x300.jpg
CIPN Market: 5.4% CAGR for Chemotherapy-Induced Peripheral Neuropathy Market Worth $1.17 Billion, Globally, by 2028: The Insight Partners
May 26, 2022 15:07 ET | The Insight Partners
New York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global...
Neuropathix_Logo_wTag.png
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
May 06, 2021 09:00 ET | Neuropathix, Inc.
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the...
TrevenaLogo.jpg
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
December 10, 2020 08:43 ET | Trevena Inc.
-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain
January 14, 2020 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife_logo_w-Tag.png
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
May 21, 2019 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and...
PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...
PledPharma presenterar läkemedelskandidaten PledOx® fas III-program på global cancerkonferens
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma
January 10, 2019 02:00 ET | PledPharma AB
Stockholm, January 10, 2019. PledPharma AB (publ) and Solasia Pharma K.K. announces that the first patient has been included in the global Phase III program for the drug candidate PledOx® in Japan....
PledPharma erhåller 600 MJPY, cirka 49 MSEK, i samband med inklusion av den första asiatiska patienten i det globala fas III programmet för PledOx®
January 10, 2019 02:00 ET | PledPharma AB
Stockholm, 10 januari 2019. PledPharma AB (publ) och Solasia Pharma K.K. meddelar att den första patienten i Japan har inkluderats till det globala fas III‑programmet för läkemedelskandidaten PledOx®....
The first patient included in PledPharma’s global Phase III program for PledOx®
November 08, 2018 02:00 ET | PledPharma AB
STOCKHOLM, November 8, 2018 — PledPharma AB (publ), a Swedish pharmaceutical developer, today announced that the first patient has been enrolled in the company’s global Phase III program with the...